Background
• Filgrastim-sndz, the first biosimilar approved in the US, has been available since September 2015 1
• Like all G-CSFs, filgrastim-sndz is typically administered by a healthcare provider 1
• US expenditures on biologic drugs have continued to grow, from an estimated $106.7 billion (Bn) in 2016 to $120.1 Bn in 2017; however, competition from the handful of biosimilars available in the US represents less than 1% of the annual biologic spend 2, 3 • Research has shown slow US biosimilar uptake to date despite over 2 years on the market; in the case of filgrastim-sndz, this may be due in part to relatively modest price discounting (~15%-20%) compared with its reference agent, filgrastim 4, 5 • Filgrastim-sndz, a short-acting G-CSF, has been approved for 5 of the 6 licensed indications for filgrastim, including prophylaxis for and treatment of febrile neutropenia in patients with cancer receiving myelosuppressive chemotherapy 6 • Another short-acting G-CSF, tbo-filgrastim, is approved for only 1 of the 6 filgrastim indications 7 -Tbo-filgrastim is not approved as a biosimilar in the US, as the Food and Drug Administration (FDA) biosimilars regulatory pathway was not yet available at the time of its regulatory submission 8 • The American Society of Clinical Oncology includes filgrastim-sndz among the G-CSFs recommended for prevention of treatment-related febrile neutropenia in patients with a solid tumor or lymphoma undergoing chemotherapy 9 • This study provides an update of previous research 10 to assess whether filgrastim-sndz utilization has increased as of 2017 • The RHD database consists of unstructured data, reflecting clinicians' transcribed notes (ie, the patient record) of patients' outpatient, emergency department (ED), or inpatient healthcare encounters
• G-CSF utilization was identified from patient records, queried for mention of the following:
-Short-acting G-CSFs: "filgrastim" or "Neupogen"; "tbo-filgrastim", "Granix", or "Neutroval"; "filgrastim-sndz", "Zarxio", or "Zarzio"
-Long-acting G-CSFs: "pegfilgrastim" or "Neulasta"
• Data included either the physicians' intention-to-treat with a G-CSF at the time of consultation or upon discharge, G-CSF treatment history, or both
• Abbreviated examples of the unstructured data are shown in ( Figure 2) • Structured data were generated from patient records to provide the annual percentage share of G-CSFs received by unique patients, which was compared annually over the study period 
Results
• A total of 38,253 mentions were identified for all G-CSFs, which were attributable to 21,479 patients visiting 9096 different providers ( • Annual trends for 2015-2017 show the long-acting G-CSF, pegfilgrastim, dominating utilization, along with a modest uptake of filgrastim-sndz over the study period ( Table 2) • In 2015, a total of 2,847 G-CSF mentions were identified, comprising the following:
-Pegfilgrastim: 71.0%; filgrastim: 28.1%; tbo-filgrastim: 0.9%; filgrastim-sndz: 0%
• In 2016, counts increased to 14,382 G-CSF mentions, reflecting growth in the number of participating providers in the RHD database and also a reduction in the share of pegfilgrastim mentions -Pegfilgrastim: 53.3%; filgrastim: 36.0%; tbo-filgrastim: 10.0%; filgrastim-sndz: 0.8%
• In 2017, despite a further increase to 21,022 G-CSF mentions as new providers were added to the database, the distribution of agents did not materially differ compared with 2016 -Pegfilgrastim: 51.7%; filgrastim: 39.3%, tbo-filgrastim: 8.1%; filgrastim-sndz: 0.9% 
Conclusions
• Among 38,253 records reporting a G-CSF in the RHD medical transcription database, only 295 mentions (0.8%) of filgrastim-sndz among 214 patients (1.0%) were documented in the more than 2 years since its entry into the US marketplace, with almost no observable increase in mentions between 2016 and 2017
• Greater utilization of long-acting pegfilgrastim compared with short-acting G-CSFs may be a factor in the low uptake of filgrastim-sndz, as may be minimal pricing discounts compared with reference agent filgrastim and limited incentives for provider use
• Further research is needed to understand the factors driving US biosimilars uptake
• Raising awareness and understanding of biosimilars among US clinicians and payers, as well as availability of additional approved biosimilars to provide greater competition and pricing pressure, is likely required for greater utilization in clinical practice
